Literature DB >> 32975758

Effects of Antipsychotic Drugs: Cross Talk Between the Nervous and Innate Immune System.

Ayushi Anna Dinesh1, Juned Islam1, Javad Khan1, Federico Turkheimer2,3, Anthony C Vernon4,5.   

Abstract

Converging lines of evidence suggest that activation of microglia (innate immune cells in the central nervous system [CNS]) is present in a subset of patients with schizophrenia. The extent to which antipsychotic drug treatment contributes to or combats this effect remains unclear. To address this question, we reviewed the literature for evidence that antipsychotic exposure influences brain microglia as indexed by in vivo neuroimaging and post-mortem studies in patients with schizophrenia and experimental animal models. We found no clear evidence from clinical studies for an effect of antipsychotics on either translocator protein (TSPO) radioligand binding (an in vivo neuroimaging measure of putative gliosis) or markers of brain microglia in post-mortem studies. In experimental animals, where drug and illness effects may be differentiated, we also found no clear evidence for consistent effects of antipsychotic drugs on TSPO radioligand binding. By contrast, we found evidence that chronic antipsychotic exposure may influence central microglia density and morphology. However, these effects were dependent on the dose and duration of drug exposure and whether an immune stimulus was present or not. In the latter case, antipsychotics were generally reported to suppress expression of inflammatory cytokines and inducible inflammatory enzymes such as cyclooxygenase and microglia activation. No clear conclusions could be drawn with regard to any effect of antipsychotics on brain microglia from current clinical data. There is evidence to suggest that antipsychotic drugs influence brain microglia in experimental animals, including possible anti-inflammatory actions. However, we lack detailed information on how these drugs influence brain microglia function at the molecular level. The clinical relevance of the animal data with regard to beneficial treatment effects and detrimental side effects of antipsychotic drugs also remains unknown, and further studies are warranted.

Entities:  

Year:  2020        PMID: 32975758     DOI: 10.1007/s40263-020-00765-x

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  153 in total

1.  Slow and latent viruses in schizophrenia.

Authors:  E F Torrey; M R Peterson
Journal:  Lancet       Date:  1973-07-07       Impact factor: 79.321

2.  Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.

Authors:  Mohammad-Reza Khodaie-Ardakani; Omid Mirshafiee; Mehdi Farokhnia; Masih Tajdini; Seyed-Mohammad-Reza Hosseini; Amirhossein Modabbernia; Farzin Rezaei; Bahman Salehi; Habibeh Yekehtaz; Mandana Ashrafi; Mina Tabrizi; Shahin Akhondzadeh
Journal:  Psychiatry Res       Date:  2014-01-09       Impact factor: 3.222

3.  Possible antipsychotic effects of minocycline in patients with schizophrenia.

Authors:  Tsuyoshi Miyaoka; Rei Yasukawa; Hideaki Yasuda; Maiko Hayashida; Takuji Inagaki; Jun Horiguchi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-10-05       Impact factor: 5.067

4.  Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment.

Authors:  Imran B Chaudhry; Jaime Hallak; Nusrat Husain; Fareed Minhas; John Stirling; Paul Richardson; Serdar Dursun; Graham Dunn; Bill Deakin
Journal:  J Psychopharmacol       Date:  2012-04-23       Impact factor: 4.153

5.  Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia.

Authors:  Yechiel Levkovitz; Uri Levi; Yoram Braw; Hagit Cohen
Journal:  Brain Res       Date:  2007-04-01       Impact factor: 3.252

6.  A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia.

Authors:  Yechiel Levkovitz; Shlomo Mendlovich; Sharon Riwkes; Yoram Braw; Hana Levkovitch-Verbin; Gilad Gal; Shmuel Fennig; Ilan Treves; Shmuel Kron
Journal:  J Clin Psychiatry       Date:  2009-11-03       Impact factor: 4.384

7.  Mice haploinsufficient for Map2k7, a gene involved in neurodevelopment and risk for schizophrenia, show impaired attention, a vigilance decrement deficit and unstable cognitive processing in an attentional task: impact of minocycline.

Authors:  R L Openshaw; D M Thomson; J M Penninger; J A Pratt; B J Morris
Journal:  Psychopharmacology (Berl)       Date:  2016-10-24       Impact factor: 4.530

8.  Maternal immune activation results in complex microglial transcriptome signature in the adult offspring that is reversed by minocycline treatment.

Authors:  D Mattei; A Ivanov; C Ferrai; P Jordan; D Guneykaya; A Buonfiglioli; W Schaafsma; P Przanowski; W Deuther-Conrad; P Brust; S Hesse; M Patt; O Sabri; T L Ross; B J L Eggen; E W G M Boddeke; B Kaminska; D Beule; A Pombo; H Kettenmann; S A Wolf
Journal:  Transl Psychiatry       Date:  2017-05-09       Impact factor: 6.222

Review 9.  An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis.

Authors:  N Çakici; N J M van Beveren; G Judge-Hundal; M M Koola; I E C Sommer
Journal:  Psychol Med       Date:  2019-08-23       Impact factor: 7.723

10.  Preventive effects of minocycline in a neurodevelopmental two-hit model with relevance to schizophrenia.

Authors:  S Giovanoli; H Engler; A Engler; J Richetto; J Feldon; M A Riva; M Schedlowski; U Meyer
Journal:  Transl Psychiatry       Date:  2016-04-05       Impact factor: 6.222

View more
  7 in total

1.  Proposed protocol for the investigation of the safety and efficacy of the COVID-19 vaccine for patients with psychosis, with pilot safety findings from a Chinese psychiatrist's self-experiment.

Authors:  Chongguang Lin; Tao Fang; Jiayue Chen; Qianchen Li; Weiliang Yang; Cong Yao; Lina Wang; Yun Sun; Ziyao Cai; Jing Ping; Ce Chen; Langlang Cheng; Jinjing Zhu; Guangdong Chen; Peiwei Shan; Chunmian Chen; Xiaodong Lin; Hongjun Tian; Chuanjun Zhuo
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

2.  Proteome Analysis of PC12 Cells Reveals Alterations in Translation Regulation and Actin Signaling Induced by Clozapine.

Authors:  Urszula Jankowska; Bozena Skupien-Rabian; Bianka Swiderska; Gabriela Prus; Marta Dziedzicka-Wasylewska; Sylwia Kedracka-Krok
Journal:  Neurochem Res       Date:  2021-05-23       Impact factor: 3.996

3.  Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis.

Authors:  Benedicto Crespo-Facorro; Miguel Ruiz-Veguilla; Javier Vázquez-Bourgon; Ana C Sánchez-Hidalgo; Nathalia Garrido-Torres; Jose M Cisneros; Carlos Prieto; Jesus Sainz
Journal:  Front Pharmacol       Date:  2021-03-02       Impact factor: 5.810

4.  A schizophrenia subgroup with elevated inflammation displays reduced microglia, increased peripheral immune cell and altered neurogenesis marker gene expression in the subependymal zone.

Authors:  Hayley F North; Christin Weissleder; Janice M Fullerton; Rachel Sager; Maree J Webster; Cynthia Shannon Weickert
Journal:  Transl Psychiatry       Date:  2021-12-15       Impact factor: 6.222

5.  Editorial: Cardiovascular and Physical Health in Severe Mental Illness.

Authors:  Sri Mahavir Agarwal; Anthony Christopher Vernon; Ganesan Venkatasubramanian; Margaret K Hahn
Journal:  Front Psychiatry       Date:  2021-09-28       Impact factor: 4.157

Review 6.  Emerging Evidence for the Widespread Role of Glutamatergic Dysfunction in Neuropsychiatric Diseases.

Authors:  Thomas McGrath; Richard Baskerville; Marcelo Rogero; Linda Castell
Journal:  Nutrients       Date:  2022-02-22       Impact factor: 5.717

7.  Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics.

Authors:  Anastasiia S Boiko; Irina A Mednova; Elena G Kornetova; Valeria I Gerasimova; Alexander N Kornetov; Anton J M Loonen; Nikolay A Bokhan; Svetlana A Ivanova
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.